27 completed. 27 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 27 | Completed 27 |
Follow Child Development Disorders, Pervasive: new trials by email Literature Review of Child Development Disorders, Pervasive trials Research Report on Child Development Disorders, Pervasive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin Gabapentin - Autism Spectrum Disorder | Phase 4 | Completed | David Cochran | 16 | 2022-02-04 | 2026-02-20 |
| Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole Comparison of Risperidone and Aripiprazole - Weight Gain, Autism Spectrum Disorder | Phase 4 | Completed | Vanderbilt University Medical Center | 30 | 2022-02-01 | 2026-10-05 |
| Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine - Non-verbal Learning Disorder, Autism Spectrum Disorder | Phase 4 | Completed | Massachusetts General Hospital | 54 | 2019-05-20 | 2025-06-05 |
| Improving Driving in Young People With Autism Spectrum Disorders Buspirone - Autism Spectrum Disorder | Phase 4 | Completed | Massachusetts General Hospital | 26 | 2018-10-31 | 2021-03-18 |
| Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Lisdexamfetamine Dimesylate - Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | Phase 4 | Completed | JPM van Stralen Medicine Professional | 48 | 2018-09-26 | 2024-02-12 |
| Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes Enhanced early detection - Autism Spectrum Disorder | Phase 4 | Completed | Drexel University | 2087 | 2017-11-29 | 2024-08-16 |
| Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder Homoeopathic medicines, Placebo, THERAPY - Autism Spectrum Disorder (ASD) | Phase 4 | Completed | Aditi Chadha | 54 | 2017-01-01 | 2025-07-08 |
| Pilot RCT Using Homeopathic Medicines in ASD Homoeopathic medicines, Therapy, Placebo - Autism Spectrum Disorder (ASD) | Phase 4 | Completed | Holistic Homoeopathic Clinic and Research Center | 54 | 2016-12-31 | 2025-11-18 |
| Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders Syntocinon (Oxytocin), Placebo (Physiological water (solution of sodium chloride (NaCl) in water)) - Autism Spectrum Disorders | Phase 4 | Completed | KU Leuven | 40 | 2015-04-01 | 2021-02-10 |
| Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR - ADHD, Autism | Phase 4 | Completed | Seattle Children's Hospital | 36 | 2014-09-01 | 2017-08-01 |
| Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Methylphenidate extended-release liquid formulation - Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder | Phase 4 | Completed | Massachusetts General Hospital | 15 | 2014-05-01 | 2024-07-01 |
| Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism ABA parent training - Autism Spectrum Disorders | Phase 4 | Completed | Federal University of São Paulo | 67 | 2014-02-01 | 2015-04-02 |
| Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder placebo, extended-release guanfacine - Pervasive Development Disorders | Phase 4 | Completed | Yale University | 62 | 2011-12-01 | 2020-03-31 |
| Omega-3 Fatty Acids in Autism Spectrum Disorders Omega-3 fatty acids - Autism Spectrum Disorders | Phase 4 | Completed | National Healthcare Group, Singapore | 60 | 2011-09-01 | 2013-05-01 |
| Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART) Aripiprazole, Risperidone - Autistic Disorder | Phase 4 | Completed | Medical University of South Carolina | 80 | 2011-07-01 | 2018-09-26 |
| Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism Milnacipran, Placebo - Autism Spectrum Disorder, Asperger Syndrome | Phase 4 | Completed | Montefiore Medical Center | 10 | 2011-02-01 | 2020-02-27 |
| A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders Memantine - Autism Spectrum Disorders | Phase 4 | Completed | Massachusetts General Hospital | 25 | 2010-01-01 | 2024-07-01 |
| A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Risperidone, Other atypical antipsychotic drugs - Schizophrenia, Bipolar Disorder | Phase 4 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 244 | 2009-10-01 | 2012-11-27 |
| FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders Aripiprazole - Autism Spectrum Disorder | Phase 4 | Completed | University of North Carolina, Chapel Hill | 13 | 2009-08-01 | 2014-03-11 |
| Atomoxetine, Placebo and Parent Management Training in Autism atomoxetine, Placebo, Parent Management Training - Autism, Pervasive Development Disorder | Phase 4 | Completed | University of Rochester | 128 | 2008-10-01 | 2016-02-04 |
Showing 20 of 27. Sign in to see all of them.
Autism Spectrum Disorder (16) · Autistic Disorder (14) · Attention Deficit Disorder with Hyperactivity (6) · Asperger Syndrome (5) · Bipolar Disorder (3) · Aggression (2) · Schizophrenia (2) · Weight Gain (2) · Anxiety Disorders (1) · Behavior (1) · Compulsive Behavior (1) · Drug-Related Side Effects and Adverse Reactions (1) · Learning Disabilities (1) · Obesity (1)
Mental Disorders (27) · Neurodevelopmental Disorders (27) · Autism Spectrum Disorder (10) · Attention Deficit and Disruptive Behavior Disorders (7) · Behavior (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Bipolar and Related Disorders (3) · Mood Disorders (3) · Social Behavior (3) · Aberrant Motor Behavior in Dementia (2) · Behavioral Symptoms (2) · Body Weight (2) · Body Weight Changes (2)
Risperidone (5) · Aripiprazole (4) · Atomoxetine Hydrochloride (2) · Fatty Acids, Omega-3 (2) · Homeopathy (2) · Therapeutics (2) · Acetylcysteine (1) · Buspirone (1) · Calcium Carbonate (1) · Causticum (1) · Datura stramonium lectin (1) · Dosage Forms (1) · Gabapentin (1) · Guanfacine (1) · Inositol (1)
Massachusetts General Hospital (4) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Montefiore Medical Center (2) · Aditi Chadha (1) · Augusta University (1) · Cambridge Health Alliance (1) · David Cochran (1) · Drexel University (1) · Eli Lilly and Company (1) · Federal University of São Paulo (1) · Holistic Homoeopathic Clinic and Research Center (1) · JPM van Stralen Medicine Professional (1) · KU Leuven (1) · Medical University of South Carolina (1) · National Healthcare Group, Singapore (1)
United States (20) · India (2) · Netherlands (2) · Belgium (1) · Brazil (1) · Canada (1) · Germany (1) · Greece (1) · Poland (1) · Singapore (1)
Eric Hollander, MD (2) · Gagan Joshi, MD (2) · Angela Maxwell-Horn, M.D. (1) · Benjamin Handen, PhD (1) · Bryan King, MD (1) · C. Lindsay DeVane, Pharm.D. (1) · Cheryl O Alderman, BS (1) · Christopher McDougle, MD (1) · David Cochran, MD (1) · Diana Robins, PhD (1) · Donna L Londino, MD (1) · Gabriel Dichter, PhD (1)
PMID 37811711, PMID 20377705, PMID 22721596, PMID 23212807, PMID 23566357, PMID 23578015, PMID 24018545, PMID 24350813, PMID 25019647, PMID 25369243, PMID 26231264, PMID 26506581, PMID 27663942, PMID 29022125, PMID 29694241, PMID 29898210, PMID 31063671, PMID 31607204, PMID 33934719, PMID 36808953, PMID 39454668
2014 (1), K23MH081285 (1), R01MH072912 (1), R01MH083707 (1)